Abstract 324P
Background
HLX10, a fully humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor blocking PD-1, increased functional activities of human T-cells and showed in-vitro antitumour activity in xenograft models. The combined inhibition of PD-1 and VEGFR pathways may enhance a sustained suppression of cancer-related angiogenesis and tumour growth. Here, we present the phase 1 study data of HLX10 and the development of HLX10 as targeted combination immunotherapy.
Methods
We conducted an open-label, dose-finding with Bayesian optimal interval adaptive design study to evaluate safety, maximum tolerated dose, PK and clinical activity of HLX10 in patients with advanced or metastatic solid tumours refractory to standard therapy. Patients (pts) received biweekly i.v. infusions of HLX10 at doses of 0.3, 1, 3 and 10 mg/kg until disease progression, intolerable toxicities or withdrawal from the study. The dose-limiting toxicities were observed for 28 days after treatment. Clinical response was evaluated every 8 weeks for the first 24 weeks followed by every 12 weeks. Safety, PK and clinical response evaluations were performed throughout the study.
Results
As of 27-June-2019, 16 pts were dosed with HLX10 at various doses and maintained >90% PD1 receptor occupancy on the peripheral T-cells. Among 13 pts being evaluated for efficacy, 2 pts each at 0.3 and 3 mg/kg cohorts achieved stable disease; 1 pt at 3 mg/kg cohort achieved partial response with the longest follow-up time of 220 days. No infusionrelated reaction or additional safety signal was observed up to 10 mg/kg. The PK profiles demonstrated dose proportional manner as shown in the table.Table:
324P The PK parameters of 0.3 mg/kg and 3 mg/kg cohorts
Dose(mg/kg) | Cmax (μg/mL) | AUC0-t (h* μg/mL) | t1/2 (h) | |||
---|---|---|---|---|---|---|
- | C1D1 | C3D1 | C1D1 | C3D1 | C1D1 | C3D3 |
0.3 | 5.3 | 6.3 | 702.1 | 957.1 | 183.4 | 183.0 |
3 | 74.8 | 117.2 | 10823.6 | 27750.9 | 259.7 | 489.81 |
Conclusions
HLX10 is well tolerated, shows promising antitumour activities with durable objective responses in various cancers, and exhibits similar PK results to pembrolizumab and nivolumab. HLX10 is currently being tested in the first China combo-immunotherapy studies with HLX04 (a bevacizumab biosimilar) in advanced solid tumours with the longest follow-up time of > 200 days as of 20-June-2019 and in first-line treatment of metastatic NSCLC.
Clinical trial identification
HLX10-001(Registration Number: NCT0346875) monotherapy in advanced solid tumours; HLX10HLX04-001(Registration Number: NCT03757936) combo-immunotherapy in advanced solid tumours; HLX10-002-NSCLC301(Registration Number: NCT03952403) combo-immunotherapy in NSCLC.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc; Taiwan Henlix Biotech., Co.,LTD.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
T.Y. Chao: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Ho: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W.H. Cheng: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. C.L. Chang: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. Y.Y. Hsieh: Research grant / Funding (institution): Taiwan Henlix Biotech., Co., LTD. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech,Inc. A. LUK: Full / Part-time employment: Shanghai Henlius Biotech, Inc. S.F. Lin: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. T.C. Hsieh: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD. E. Liu: Full / Part-time employment: Taiwan Henlix Biotech., Co., LTD.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract